Faculty profile

Andrew Freywald

ResearcherOncologyUniversity of Saskatchewan

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Saskatchewan directory, so their courses may be missing. Find their university profile.

Andrew Freywald

Researcher

Oncology

Health Sciences

University of Saskatchewan

Saskatoon, Saskatchewan, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
17 publications in the last five years, latest in 2026.
Senior (last) author on 2 recent papers, a sign of leading a research group.
Principal investigator on 6 research grants (6 CIHR), most recently in 2025.
Supervised 1 trainee who won CIHR awards, most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Synthetic Dosage Lethality Telomerase Pancreatic Cancer Bispecific Antibody Breast Cancer Genome-Wide Crispr Screening Radioconjugates Genome-Wide Crispr And Shrna Screens

Latest papers

Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancers.
Signal transduction and targeted therapy · 2026
A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancer.
Oncogene · 2025
The DRP1 receptor FIS1 is critical to the expansion of triple-negative breast cancer tumor-initiating cells.
Cancer cell international · 2025

All 61 publications

Latest funding

Telomere-Directed Epigenetic Therapy: A Novel Approach for Treating Pancreatic Ductal Adenocarcinoma.
CIHR · 2025 · Principal investigator
$1,105,426
Targeting the EGFR/EphA2 crosstalk in triple negative breast cancer
CIHR · 2023 · Nominated PI
$100,000
Targeting mitochondrial fission machinery in tumor-initiating cells
CIHR · 2022 · Co-investigator
$59,609

All 8 grants and awards

61 publications.

Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancers.

Price JDW, Vizeacoumar FS, Abuhussein O, Maranda V, Zhang Y, Adachi H, Nguyen K, Kyrylenko L, Rangel-Pozzo A, Dong H, Gong L, Materi A, Walke P, Ganapathysamy A, Denomy C, Freywald T, Dahiya R, Elhasasna H, Saxena A, Vizeacoumar JP, Patel H, Rajamanickam K, de Oliveira DM, Lazell-Wright M, Morales AM, Aggarwal A, Xu JL, Alli N, Munhoz EP, Gao P, Salsman J, Dahiya DK, Kola NS, Gonzalez-Lopez C, Thibault P, Levin M, Dellaire G, Jette N, Groot G, Köbel M, Lee CH, Hopkins L, Krishnan A, Ahmed S, Eskiw C, Barakat KH, Thakur A, Wu Y, DePinho RA, Mai S, Yu YT, Wong JMY, Freywald A, Vizeacoumar FJ

Signal transduction and targeted therapy2026

DOI: 10.1038/s41392-026-02750-0 PMID: 42236690

A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancer.

Walke P, Price JDW, Vizeacoumar FS, Joseph N, Maranda V, Chowdhury B, Patel J, Zhang Y, Dong H, New L, Ganapathysamy A, Gong LH, Lazell-Wright M, Elhasasna H, Bhanumathy KK, Wu Y, Wang Y, Freywald A, Krishnan A, Vizeacoumar FJ

Oncogene2025

DOI: 10.1038/s41388-025-03413-0 PMID: 40301542

The DRP1 receptor FIS1 is critical to the expansion of triple-negative breast cancer tumor-initiating cells.

Katrii T, Freywald T, Estrada MG, El Zawily A, Toosi B, Vizeacoumar FS, Vizeacoumar FJ, Freywald A, Leary SC

Cancer cell international2025

DOI: 10.1186/s12935-025-03909-5 PMID: 40684193

EGFR Phosphorylates and Associates with EFNB1 to Regulate Cell Adhesion to Fibronectin.

Osornio-Hernández AI, Chartier FJM, Schuehle TL, Banerjee SL, Elowe S, Laprise P, Freywald A, Laurin M, Bisson N

Molecular & cellular proteomics : MCP2025

DOI: 10.1016/j.mcpro.2025.101027 PMID: 40619000

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethality.

Cunningham CE, Vizeacoumar FS, Zhang Y, Kyrylenko L, Both S, Maranda V, Dong H, Price JDW, Gao P, Wagner K, Wu Y, Lazell-Wright M, Ganapathysamy A, Hari R, Bhanumathy KK, Denomy C, Saxena A, Vizeacoumar JP, Morales AM, Khan F, Mosley S, Chen A, Katrii T, Zoller BGE, Rajamanickam K, Walke P, Gong L, Patel H, Elhasasna H, Dahiya R, Abuhussein O, Dmitriev A, Freywald T, Munhoz EP, Ruppin E, Lee JS, Rox K, Koebel M, Hopkins L, Lee CH, Yadav S, Gasparoni G, Walter J, Krishnan A, Datla R, Toosi B, Baker K, Meens J, Cescon DW, Ailles L, Leary SC, Wu Y, Empting M, Kiemer AK, Freywald A, Vizeacoumar FJ

Cell genomics2025

DOI: 10.1016/j.xgen.2025.100876 PMID: 40347943

Cancer Cell's Achilles Heels: Considerations for Design of Anti-Cancer Drug Combinations.

Gahramanov V, Vizeacoumar FS, Morales AM, Bonham K, Sakharkar MK, Kumar S, Vizeacoumar FJ, Freywald A, Sherman MY

International journal of molecular sciences2024

DOI: 10.3390/ijms252413495 PMID: 39769257

Systematic Comparison of CRISPR and shRNA Screens to Identify Essential Genes Using a Graph-Based Unsupervised Learning Model.

Ding Y, Denomy C, Freywald A, Pan Y, Vizeacoumar FJ, Vizeacoumar FS, Wu FX

Cells2024

DOI: 10.3390/cells13191653 PMID: 39404416

Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer.

Kumar PP, Smith D, Key J, Dong H, Ganapathysamy A, Maranda V, Wong NKY, Fernandez ML, Kim H, Zhang G, Ewanowich C, Hopkins L, Freywald A, Postovit LM, Köbel M, Fu Y, Vizeacoumar FS, Vizeacoumar FJ, Carey MS, Lee CH

Gynecologic oncology2024

DOI: 10.1016/j.ygyno.2024.06.029 PMID: 38970843

MEMO1 binds iron and modulates iron homeostasis in cancer cells.

Dolgova N, Uhlemann EE, Boniecki MT, Vizeacoumar FS, Ara A, Nouri P, Ralle M, Tonelli M, Abbas SA, Patry J, Elhasasna H, Freywald A, Vizeacoumar FJ, Dmitriev OY

eLife2024

DOI: 10.7554/elife.86354 PMID: 38640016

Breast Tumor Metastasis and Its Microenvironment: It Takes Both Seed and Soil to Grow a Tumor and Target It for Treatment.

Bonni S, Brindley DN, Chamberlain MD, Daneshvar-Baghbadorani N, Freywald A, Hemmings DG, Hombach-Klonisch S, Klonisch T, Raouf A, Shemanko CS, Topolnitska D, Visser K, Vizeacoumar FJ, Wang E, Gibson SB

Cancers2024

DOI: 10.3390/cancers16050911 PMID: 38473273

Something wrong or missing on this profile? Suggest a correction

Andrew Freywald

Research

Latest papers

Latest funding

Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancers.

A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancer.

The DRP1 receptor FIS1 is critical to the expansion of triple-negative breast cancer tumor-initiating cells.

EGFR Phosphorylates and Associates with EFNB1 to Regulate Cell Adhesion to Fibronectin.

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethality.

Cancer Cell's Achilles Heels: Considerations for Design of Anti-Cancer Drug Combinations.

Systematic Comparison of CRISPR and shRNA Screens to Identify Essential Genes Using a Graph-Based Unsupervised Learning Model.

Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer.

MEMO1 binds iron and modulates iron homeostasis in cancer cells.

Breast Tumor Metastasis and Its Microenvironment: It Takes Both Seed and Soil to Grow a Tumor and Target It for Treatment.

Frequent collaborators

Jim Xiang

Anand Krishnan

Shahid Ahmed

Mohan Babu

Nicolas Bisson

Anthony Kusalik

Maruti Uppalapati

Gary Groot

Darrell Mousseau

Zhaolei Zhang

Kristi Baker

Sabine Hombach-Klonisch

Patrick Laprise

Christopher Eskiw

Edwin Wang

Edana Cassol

Aneesh Thakur

Yue Chen

Humphrey Fonge

Peter Siegel

Thomas Klonisch

Ashok Kumar

Sabine Elowe

Sylvia Van Drunen Littel-van den Hurk

Yuzhuo Wang

Laurie Ailles

Sabine Mai

Deborah Anderson